


George Robert Jackson, M.D., Ph.D.

- **Professor of Neurology**

Baylor College of Medicine

- **Associate Director, Research,
Parkinson's Disease Research, Education and Clinical Center
(PADRECC)**

Michael E. DeBakey Veterans Affairs Medical Center



CONTACT INFORMATION

George Robert Jackson, M.D., Ph.D.
Parkinson's Disease Research Education and Clinical Center
Michael E. DeBakey VA Medical Center
2002 Holcombe Blvd.
Houston, Texas 77030

Tel: 713-794-8936
Fax: 713-794-8888
Email: George.Jackson2@bcm.edu

CERTIFICATION

- American Board of Psychiatry and Neurology, Neurology

EDUCATION

- M.D., The University of Texas, Medical Branch at Galveston, Texas
- Ph.D., The University of Texas, Medical Branch at Galveston, Texas
- M.A., The University of Texas, Austin, Texas
- B.S., The University of Texas, Austin, Texas
- Internship, Internal Medicine, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, Calif.
- Residency, Neurology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, Calif.
- Fellowship, Neurogenetics, Howard Hughes Medical Institute, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, Calif.
- Fellowship, Movement Disorders, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, Calif.

CLINICAL INTERESTS

Pathogenesis, diagnosis, therapy and management of neurodegenerative movement disorders/dementias

JOURNAL PUBLICATIONS

1. Newsome MR, Martindale SL, Davenport N, Dennis EL, Diaz M, Esopenko C, et al. Subcortical functional connectivity and its association with walking performance following deployment related mild TBI. *Front Neurol.* 2023;14:1276437. PMID: 38156092.
2. Yusuff T, Chang YC, Sang TK, Jackson GR, Chatterjee S. Codon-optimized TDP-43 mediates neurodegeneration in a *Drosophila* model of ALS/FTLD. *Front Genet.* 2023;14:881638. PMID: 36968586.
3. Shah C, Jackson GR, Sarwar AI, Mandava P, Jamal F. Treatment patterns in essential tremor: A retrospective analysis. *Tremor Other Hyperkinet Mov (N Y).* 2022;12:10. PMID: 35415009.
4. Troyanskaya M, Pastorek NJ, Jamal F, Jackson GR, Sarwar AI, Wilde EA, et al. A pilot study of olfactory function in veterans with a history of deployment-related mild traumatic brain injury. *Neurocase.* 2022;1-8. PMID: 36576237.
5. Derry PJ, Hegde ML, Jackson GR, Kayed R, Tour JM, Kent TA, et al. Revisiting the intersection of amyloid,

- pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective. *Prog Neurobiol.* 2020;184:101716. PMID: 31604111.
- 6. Chatterjee S, Ambegaokar SS, Jackson GR, Mudher A. Insulin-mediated changes in tau hyperphosphorylation and autophagy in a Drosophila model of tauopathy and neuroblastoma cells. *Front Neurosci.* 2019;13:801. PMID: 31427921.
 - 7. Bryant MS, Workman CD, Jamal F, Meng H, Jackson GR. Feasibility study: Effect of hand resistance exercise on handwriting in Parkinson's disease and essential tremor. *J Hand Ther.* 2018;31(1):29-34. PMID: 28389133.
 - 8. Jackson GR. Lifestyles of a toxic twosome: A novel tau strain induced by alpha-synuclein oligomers. *Biol Psychiatry.* 2018;84(7):472-3. PMID: 30176989.
 - 9. Jackson GR. SCA31 flies perform in a balancing act between RAN translation and RNA-binding proteins. *Neuron.* 2017;94(1):4-5. PMID: 28384473.
 - 10. Chouhan AK, Guo C, Hsieh YC, Ye H, Senturk M, Zuo Z, et al. Uncoupling neuronal death and dysfunction in Drosophila models of neurodegenerative disease. *Acta Neuropathol Commun.* 2016;4(1):62. PMID: 27338814.
 - 11. Iyer J, Wang Q, Le T, Pizzo L, Gronke S, Ambegaokar SS, et al. Quantitative assessment of eye phenotypes for functional genetic studies using Drosophila melanogaster. *G3 (Bethesda).* 2016;6(5):1427-37. PMID: 26994292.
 - 12. Sengupta U, Guerrero-Munoz MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, Paulucci-Holthauzen AA, et al. Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies. *Biol Psychiatry.* 2015;78(10):672-83. PMID: 25676491.
 - 13. Bakhoun MF, Bakhoun CY, Ding Z, Carlton SM, Campbell GA, Jackson GR. Evidence for autophagic gridlock in aging and neurodegeneration. *Transl Res.* 2014;164(1):1-12. PMID: 24561013.
 - 14. Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. *J Neurosci.* 2014;34(12):4260-72. PMID: 24647946.
 - 15. Choksi DK, Roy B, Chatterjee S, Yusuff T, Bakhoun MF, Sengupta U, et al. TDP-43 phosphorylation by casein kinase epsilon promotes oligomerization and enhances toxicity in vivo. *Hum Mol Genet.* 2014;23(4):1025-35. PMID: 24105464.
 - 16. Guerrero-Munoz MJ, Castillo-Carranza DL, Krishnamurthy S, Paulucci-Holthauzen AA, Sengupta U, Lasagna-Reeves CA, et al. Amyloid-beta oligomers as a template for secondary amyloidosis in Alzheimer's disease. *Neurobiol Dis.* 2014;71:14-23. PMID: 25134727.
 - 17. Jackson GR. Learn to forget: Regulation of age-related memory impairment by neuronal-glial crosstalk. *Neuron.* 2014;84(4):658-9. PMID: 25459404.
 - 18. Roy B, Jackson GR. Interactions between tau and alpha-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. *Hum Mol Genet.* 2014;23(11):3008-23. PMID: 24430504.
 - 19. Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier). *Alzheimers Dement.* 2013;9(2):189-98. PMID: 23062850.
 - 20. Hawkins BE, Krishnamurthy S, Castillo-Carranza DL, Sengupta U, Prough DS, Jackson GR, et al. Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: Possible link between traumatic brain injury and sporadic tauopathies. *J Biol Chem.* 2013;288(23):17042-50. PMID: 23632019.
 - 21. Wightman PJ, Jackson GR, Dipple KM. Disruption of glycerol metabolism by RNAi targeting of genes encoding glycerol kinase results in a range of phenotype severity in Drosophila. *PLoS One.* 2013;8(9):e71664. PMID: 24039719.
 - 22. Ambegaokar SS, Jackson GR. The downward spiral of tau and autolysosomes: a new hypothesis in neurodegeneration. *Autophagy.* 2012;8(7):1144-5. PMID: 22635052.
 - 23. Klionsky DJ, Abdalla FC, Abieliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy.* 2012;8(4):445-544. PMID: 22966490.
 - 24. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. *Sci Rep.* 2012;2:700. PMID: 23050084.
 - 25. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. *Faseb J.* 2012;26(5):1946-59. PMID: 22253473.
 - 26. Wightman PJ, Jackson GR, Dipple KM. Glycerol hypersensitivity in a Drosophila model for glycerol kinase deficiency is affected by mutations in eye pigmentation genes. *PLoS One.* 2012;7(3):e31779. PMID: 22427807.
 - 27. Ambegaokar SS, Jackson G. Double vision: Pigment genes do more than just color. *Fly (Austin).* 2011;5(3):206-9. PMID: 21406968.
 - 28. Ambegaokar SS, Jackson GR. Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. *Hum Mol Genet.* 2011;20(24):4947-77. PMID: 21949350.

29. Bakhoum MF, Jackson GR. Demise of the flies: Why Drosophila models still matter. *Prog Mol Biol Transl Sci.* 2011;100:483-98. PMID: 21377634.
30. Chang YC, Hung WT, Chang HC, Wu CL, Chiang AS, Jackson GR, et al. Pathogenic VCP/TER94 alleles are dominant actives and contribute to neurodegeneration by altering cellular ATP level in a Drosophila IBMPFD model. *PLoS Genet.* 2011;7(2):e1001288. PMID: 21304887.
31. Clos AL, Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Jackson GR, Kelly B, et al. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis. *Br J Dermatol.* 2011;165(6):1349-54. PMID: 21729025.
32. Clos AL, Lasagna-Reeves CA, Kelly B, Wagner R, Wilkerson M, Jackson GR, et al. Role of oligomers in the amyloidogenesis of primary cutaneous amyloidosis. *J Am Acad Dermatol.* 2011;65(5):1023-31. PMID: 21669474.
33. Kayed R, Jackson GR, Estes DM, Barrett AD. Alzheimers disease: Review of emerging treatment role for intravenous immunoglobulins. *J Cent Nerv Syst Dis.* 2011;3:67-73. PMID: 23861639.
34. Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. *Curr Alzheimer Res.* 2011;8(6):659-65. PMID: 21605039.
35. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. *Mol Neurodegener.* 2011;6:39. PMID: 21645391.
36. Ambegaokar SS, Jackson GR. Interaction between eye pigment genes and tau-induced neurodegeneration in *Drosophila melanogaster*. *Genetics.* 2010;186(1):435-42. PMID: 20592261.
37. Ambegaokar SS, Roy B, Jackson GR. Neurodegenerative models in *Drosophila*: Polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis. *Neurobiol Dis.* 2010;40(1):29-39. PMID: 20561920.
38. Barrett AD, Kayed R, Jackson GR, Cunningham KA. New vaccine development for chronic brain disease. *Neuropsychopharmacology.* 2010;35(1):354. PMID: 20010720.
39. Clos AL, Lasagna-Reeves CA, Wagner R, Kelly B, Jackson GR, Kayed R. Therapeutic removal of amyloid deposits in cutaneous amyloidosis by localised intra-lesional injections of anti-amyloid antibodies. *Exp Dermatol.* 2010;19(10):904-11. PMID: 20626464.
40. Langbehn DR, Hayden MR, Paulsen JS, Predict-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. *Am J Med Genet B Neuropsychiatr Genet.* 2010;153B(2):397-408. PMID: 19548255.
41. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R. Preparation and characterization of neurotoxic tau oligomers. *Biochemistry.* 2010;49(47):10039-41. PMID: 21047142.
42. Lasagna-Reeves CA, Clos AL, Midoro-Hiruti T, Goldblum RM, Jackson GR, Kayed R. Inhaled insulin forms toxic pulmonary amyloid aggregates. *Endocrinology.* 2010;151(10):4717-24. PMID: 20685871.
43. Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. *Brain Res Bull.* 2010;82(3-4):201-7. PMID: 20385209.
44. Quaid KA, Swenson MM, Sims SL, Harrison JM, Moskowitz C, Stepanov N, et al. What were you thinking? Individuals at risk for Huntington Disease talk about having children. *J Genet Couns.* 2010;19(6):606-17. PMID: 20734119.
45. Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, et al. Motor abnormalities in premanifest persons with Huntington's disease: The PREDICT-HD study. *Mov Disord.* 2009;24(12):1763-72. PMID: 19562761.
46. Chatterjee S, Sang TK, Lawless GM, Jackson GR. Dissociation of tau toxicity and phosphorylation: Role of GSK-3beta, MARK and Cdk5 in a *Drosophila* model. *Hum Mol Genet.* 2009;18(1):164-77. PMID: 18930955.
47. Kayed R, Jackson GR. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. *Curr Opin Immunol.* 2009;21(3):359-63. PMID: 19482462.
48. Kuo SH, Jackson GR. Emerging subspecialties in neurology: Translational research in movement disorders. *Neurology.* 2009;73(8):e40-1. PMID: 19704074.
49. Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, et al. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. *J Neurosci.* 2009;29(7):1962-76. PMID: 19228951.
50. Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I, et al. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. *Neurology.* 2009;73(5):385-92. PMID: 19652143.
51. Jackson GR. Guide to understanding *Drosophila* models of neurodegenerative diseases. *PLoS Biol.* 2008;6(2):e53. PMID: 18303955.
52. Oster E, Dorsey ER, Bausch J, Shinaman A, Kayson E, Oakes D, et al. Fear of health insurance loss among individuals at risk for Huntington disease. *Am J Med Genet A.* 2008;146A(16):2070-7. PMID: 18627059.
53. Ratnaparkhi A, Lawless GM, Schweizer FE, Golshani P, Jackson GR. A *Drosophila* model of ALS: Human

- ALS-associated mutation in VAP33A suggests a dominant negative mechanism. *PLoS One.* 2008;3(6):e2334. PMID: 18523548.
54. Schaffer BA, Bertram L, Miller BL, Mullin K, Weintraub S, Johnson N, et al. Association of GSK3B with Alzheimer disease and frontotemporal dementia. *Arch Neurol.* 2008;65(10):1368-74. PMID: 18852354.
 55. Sang TK, Chang HY, Lawless GM, Ratnaparkhi A, Mee L, Ackerson LC, et al. A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. *J Neurosci.* 2007;27(5):981-92. PMID: 17267552.
 56. Doglio LE, Kanwar R, Jackson GR, Perez M, Avila J, Dingwall C, et al. gamma-cleavage-independent functions of presenilin, nicastrin, and Aph-1 regulate cell-junction organization and prevent tau toxicity in vivo. *Neuron.* 2006;50(3):359-75. PMID: 16675392.
 57. Fogel B, Wu M, Kremen S, Murthy K, Jackson G, Vanek Z. Creutzfeldt-Jakob disease presenting with alien limb sign. *Mov Disord.* 2006;21(7):1040-2. PMID: 16552737.
 58. Huntington Study Group PHAROS Investigators. At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. *Arch Neurol.* 2006;63(7):991-6. PMID: 16831969.
 59. Karsten SL, Sang TK, Gehman LT, Chatterjee S, Liu J, Lawless GM, et al. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. *Neuron.* 2006;51(5):549-60. PMID: 16950154.
 60. Sengupta S, Horowitz PM, Karsten SL, Jackson GR, Geschwind DH, Fu Y, et al. Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro. *Biochemistry.* 2006;45(50):15111-9. PMID: 17154549.
 61. Slepko N, Bhattacharyya AM, Jackson GR, Steffan JS, Marsh JL, Thompson LM, et al. Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteins. *Proc Natl Acad Sci U S A.* 2006;103(39):14367-72. PMID: 16980414.
 62. Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, et al. Interrater agreement in the assessment of motor manifestations of Huntington's disease. *Mov Disord.* 2005;20(3):293-7. PMID: 15584032.
 63. Mee L, Honkala H, Kopra O, Vesa J, Finnila S, Visapaa I, et al. Hydrolethalus syndrome is caused by a missense mutation in a novel gene HYLS1. *Hum Mol Genet.* 2005;14(11):1475-88. PMID: 15843405.
 64. Sang TK, Jackson GR. Drosophila models of neurodegenerative disease. *NeuroRx.* 2005;2(3):438-46. PMID: 16389307.
 65. Sang TK, Li C, Liu W, Rodriguez A, Abrams JM, Zipursky SL, et al. Inactivation of Drosophila Apaf-1 related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis. *Hum Mol Genet.* 2005;14(3):357-72. PMID: 15590702.
 66. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. *Neuron.* 2002;34(4):509-19. PMID: 12062036.
 67. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. *Nature.* 2001;413(6857):739-43. PMID: 11607033.
 68. Jackson GR, Salecker I, Dong X, Yao X, Arnhem N, Faber PW, et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. *Neuron.* 1998;21(3):633-42. PMID: 9768849.
 69. Pan Z, Sampath D, Jackson G, Werrbach-Perez K, Perez-Polo R. Nerve growth factor and oxidative stress in the nervous system. *Adv Exp Med Biol.* 1997;429:173-93. PMID: 9413574.
 70. Jackson GR, Sampath D, Werrbach-Perez K, Perez-Polo JR. Effects of nerve growth factor on catalase and glutathione peroxidase in a hydrogen peroxide-resistant pheochromocytoma subclone. *Brain Res.* 1994;634(1):69-76. PMID: 8156393.
 71. Jackson GR, Werrbach-Perez K, Pan Z, Sampath D, Perez-Polo JR. Neurotrophin regulation of energy homeostasis in the central nervous system. *Dev Neurosci.* 1994;16(5-6):285-90. PMID: 7768207.
 72. Sampath D, Jackson GR, Werrbach-Perez K, Perez-Polo JR. Effects of nerve growth factor on glutathione peroxidase and catalase in PC12 cells. *J Neurochem.* 1994;62(6):2476-9. PMID: 8189251.
 73. Foreman PJ, Taglialatela G, Jackson GR, Perez-Polo JR. Dexamethasone blocks nerve growth factor induction of nerve growth factor receptor mRNA in PC12 cells. *J Neurosci Res.* 1992;31(1):52-7. PMID: 1319504.
 74. Jackson GR, Werrbach-Perez K, Ezell EL, Post JF, Perez-Polo JR. Nerve growth factor effects on pyridine nucleotides after oxidant injury of rat pheochromocytoma cells. *Brain Res.* 1992;592(1-2):239-48. PMID: 1450913.
 75. Taglialatela G, Angelucci L, Ramacci MT, Werrbach-Perez K, Jackson GR, Perez-Polo JR. Stimulation of nerve growth factor receptors in PC12 by acetyl-L-carnitine. *Biochem Pharmacol.* 1992;44(3):577-85. PMID: 1324679.
 76. Jackson GR, Morgan BC, Werrbach-Perez K, Perez-Polo JR. Antioxidant effect of retinoic acid on PC12 rat pheochromocytoma. *Int J Dev Neurosci.* 1991;9(2):161-70. PMID: 1647645.
 77. Taglialatela G, Angelucci L, Ramacci MT, Werrbach-Perez K, Jackson GR, Perez-Polo JR. Acetyl-L-carnitine enhances the response of PC12 cells to nerve growth factor. *Brain Res Dev Brain Res.* 1991;59(2):221-30. PMID: 1655307.

78. Jackson GR, Apffel L, Werrbach-Perez K, Perez-Polo JR. Role of nerve growth factor in oxidant-antioxidant balance and neuronal injury. I. Stimulation of hydrogen peroxide resistance. *J Neurosci Res.* 1990;25(3):360-8. PMID: 2325161.
79. Jackson GR, Werrbach-Perez K, Perez-Polo JR. Role of nerve growth factor in oxidant-antioxidant balance and neuronal injury. II. A conditioning lesion paradigm. *J Neurosci Res.* 1990;25(3):369-74. PMID: 2325162.
80. Perez-Polo JR, Foreman PJ, Jackson GR, Shan D, Taglialatela G, Thorpe LW, et al. Nerve growth factor and neuronal cell death. *Mol Neurobiol.* 1990;4(1-2):57-91. PMID: 2076219.
81. Werrbach-Perez K, Jackson G, Marchetti D, Morgan B, Thorpe L, Perez-Polo JR. Growth factor-mediated protection in aging CNS. *Prog Brain Res.* 1990;86:183-94. PMID: 1965052.

BOOK CHAPTERS and OTHER PUBLICATIONS

1. Jackson GR. Non-Alzheimer's dementias. In: Kass JS, Mizrahi EM, editors. *Neurology secrets.* 6th ed. Philadelphia: Elsevier; 2016. p. 201-205.
2. Krantz DE, Jackson GR. Model organisms and neurogenetics. In: Sawa A, McInnis M, editors. *Neurogenetics of psychiatric disorders.* New York: Taylor and Francis; 2007. p. 117-134.
3. Jackson GR, Sang T, Taylor JP. Drosophila models of polyglutamine disorders. In: Wells RD, Ashizawa T, editors. *Genetic instabilities and neurological diseases.* 2nd ed. San Diego: Elsevier; 2006. p. 587-594. Available from: <http://www.sciencedirect.com/science/book/9780123694621>.
4. Jackson GR, Lang AE. Hyperkinetic movement disorders. In: Coffey CE, Cummings JL, editors. *Textbook of geriatric neuropsychiatry.* 2nd ed. Washington, DC: American Psychiatric Press; 2000. p. 531-558.
5. Jackson GR. Modeling neurodegenerative diseases in the fruit fly. In: Chesselet M-, editor. *Molecular mechanisms of neurodegenerative diseases.* Totowa, New Jersey: Humana Press; 2000. p. 373-406.
6. Jackson GR, Perez-Polo JR. Paradigms for study of neurotrophin effects in oxidant injury. In: Perez-Polo JR, editor. *Methods in neuroscience.* Vol. 30. San Diego: Academic Press; 1996. p. 1-25. Available from: <http://www.sciencedirect.com/science/article/pii/S1043947196800930>.

POSTER and PLATFORM PRESENTATIONS

1. Jackson GR, Sarwar AI, Mandava P, Jamal F. Age at onset and therapeutic efficacy of primidone in essential tremor. *Mov Disord.* 2023;38(suppl 1):S431.
2. Jamal F, Noorbhai I, Jackson G, Sarwar A. Racial differences in essential tremor. *Mov Disord.* 2022;37 Suppl 2:S427.
3. Noorbhai IZ, Jamal F, Jackson G, Sarwar A. Deep brain stimulation surgery and clinical characteristics of essential tremor in a cohort of veterans. Presented at the Movement Disorder Society (MDS), Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 17-22, 2021).
4. Shah C, Jamal F, Sarwar A, Jackson G. Use of botulinum toxin: Experience in a cohort of essential tremor patients. *Mov Disord.* 2020;35 Suppl 1:S699.
5. Shah C, Jamal F, Jackson G, Sarwar A. Treatment patterns in patients with essential tremor. *Neurology.* 2020;94(15 Suppl):1555.
6. Jamal F, Jackson GR, Moore S, Sarwar AI. Age of onset and diagnosis of essential tremor. Presented at the Movement Disorder Society (MDS), 23rd International Congress of Parkinson's Disease and Movement Disorders in Nice, France (Sept. 22-26, 2019).
7. Jamal F, Jackson GR, Moore S, Sarwar A. Vitamin D assessment in veterans with Parkinson's disease. *Neurology.* 2019;92(15 Suppl):P5.8-046.
8. Bryant M, Hou J-G, Jamal F, Jackson G, Workman C, Protas E. Predictive ability of clinical timed tests for postural instability and gait difficulty in Parkinson's disease. *Mov Disord.* 2017;32 Suppl 2:S723-4.
9. Jamal F, Jackson GR, Moore S, Sarwar AI. Vitamin D and clinical phenotypes of Parkinson's disease in veterans. *Mov Disord.* 2017;32 Suppl 2:S897.
10. Frautschy SA, Hu S, Jones MR, Yang F, Chen P, Jackson GR, et al. Effects of tau peptide aggregation inhibitor in human tau transgenic models. Program No. 513.22. 2016 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2016. Online.
11. Jackson GR, Bryant M, Zaheer F, Protas E. Safety of treadmill exercise testing in Parkinson disease. *Ann Neurol.* 2015;78 Suppl 19:S61.
12. Yassin A, Shroff S, Patel S, Parker A, Berman M, Jackson G. Hemichorea in a patient with diabetic ketoacidosis. *Neurology.* 2015;84(Meeting Abstracts 1):P3.033.
13. Jackson GR, Choksi DK, Roy B, Chatterjee S, Sengupta E, Kayed R. Casein kinase I phosphorylation of TDP-43 causes oligomerization and enhances toxicity in vivo. Presented at the Keystone Symposium, New Frontiers in Neurodegenerative Disease Research Meeting in Santa Fe, N.M. (Feb. 5, 2013).
14. Jackson GR. Dissection of tauopathy mechanisms using unbiased genetic screening in the Drosophila retina. Presented at the Biochemical Society, Conference: The biology and pathology of tau and its role in

tauopathies II in Cambridge, U.K. (Jan. 8-9, 2012). [Invited Plenary Speaker]

15. Bakhoum MF, Jackson GR. Blue cheese/Alfy affects autophagy activation and tau toxicity in a Drosophila model of tauopathy. Program No. 351.20. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online.
16. Jackson GR, Ambegaokar S. RNA binding protein hnRNP K/bancal and its intronic microRNA miR-7 exert opposite effects on tau toxicity through regulation of Insulin Receptor Substrate/chico and GSK-3beta activity. Program No. 144.01. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online.
17. Jackson GR, Ambegaokar S. An unbiased genetic screen for modifiers of tauopathy using both loss and gain of function approaches. Presented at the 2010 American Society for Cell Biology (ASCB), Annual Meeting in Philadelphia, Penn. (Dec. 11-15, 2010).
18. Castillo DL, Lasagna-Reeves C, Guerrero-Munoz MJ, Estes DM, Barrett A, Dineley K, et al. Modulation of tau oligomers by passive vaccination. Program No. 347.11. 2010 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2010. Online.
19. Kayed R, Lasagna-Reeves C, Guerrero-Munoz M, Sengupta U, Troncoso J, Jackson GR. Characterization of tau oligomers in Alzheimer's disease. Program No. 527.6. 2010 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2010. Online.
20. Roy B, Ambegaokar SS, Jackson GR. Synergistic effects of tau and alpha-synuclein in dopaminergic neurons. Program No. 458.3. 2010 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2010. Online.
21. Sengupta U, Lasagna-Reeves C, Guerrero-Munoz M, Castillo-Carranza D, Jackson GR, Troncoso J, et al. Tau oligomers in Parkinson disease and dementia with Lewy bodies and their connection with alpha-synuclein oligomers. Program No. 49.10. 2010 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2010. Online.
22. Castillo-Carranza DL, Lasagna-Reeves CA, Guerrero-Munoz MJ, Roy B, Jackson GR, Kayed R. Alpha-synuclein oligomers in Parkinson's disease and Lewy body dementia. *Mov Disord*. 2010;25 Suppl 2:S207.
23. Lasagna-Reeves CA, Jackson GR, Troncoso J, Kayed R. The formation of pore-like amyloid aggregates in movement disorders. *Mov Disord*. 2010;25 Suppl 2:S208.
24. Lasagna-Reeves CA, Roy B, Bakhoum M, Guerrero-Munoz MJ, Castillo-Carranza DL, Troncoso J, et al. Role of tau oligomers in Parkinson's disease and dementia with Lewy bodies. *Mov Disord*. 2010;25 Suppl 2:S207.
25. Ambegaokar SS, Yusuff T, Choksi DK, Kayed R, Jackson GR. Wing phenotypes produced by misexpression of an ALS-associated TDP-43 mutation include supernumerary veins: A possible clue to signaling pathways. Presented at the NINDS and ALS Association, Workshop: Advances in Disease Modeling for ALS and FTD in San Diego, Calif. (2010).